Jade Biosciences Inc.
Organization details
- Legal name
- Jade Biosciences Inc.
- Former names
- Aerovate Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- JBIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001798749
- EIN
- 83-1377888
Board of directors
-
Allison Dorval · DirectorSince 2023
-
Christopher W. Cain · DirectorSince 2025
-
David S. Grayzel · DirectorSince 2023
-
Donald J. Santel · DirectorSince 2023
-
Eric Dobmeier · DirectorSince 2025
-
Erin Lavelle · DirectorSince 2025
- Since 2023
-
Joshua Resnick · DirectorSince 2023
-
Lawrence Otto Klein · DirectorSince 2025
-
Maha Katabi · DirectorSince 2023
-
Mark Eisner · DirectorSince 2026
-
Mark T. Iwicki · DirectorSince 2023
- Since 2025
- Since 2023
- Since 2023
-
Timothy P. Noyes · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Tom Frohlich · Director · Chief Executive OfficerSince 2025
- Since 2025
Chief executives
Director election results
Annual meeting of June 8, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.0%
-
100.0%
Board connections
15 of this board's directors also sit on 46 other boards. 46 are in the same sector.
-
PepGen Inc. Same sectorvia Habib J. Dable, Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Eric Dobmeier, Peter Kolchinsky and Rajeev M. Shah
-
Oruka Therapeutics Inc. Same sectorvia Lawrence Otto Klein, Peter Evan Harwin and Tomas Kiselak
-
Sionna Therapeutics Inc. Same sectorvia Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Habib J. Dable, Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Habib J. Dable, Peter Kolchinsky and Rajeev M. Shah
-
Viridian Therapeutics Inc. Same sectorvia Christopher W. Cain, Peter Evan Harwin and Tomas Kiselak
-
Vor Biopharma Inc. Same sectorvia Joshua Resnick, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bicara Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Climb Bio Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Cogent Biosciences Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Crescent Biopharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Damora Therapeutics Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Dianthus Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Korsana Biosciences Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Q32 Bio Inc. Same sectorvia David S. Grayzel and Mark T. Iwicki
-
Septerna Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Spyre Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Zenas BioPharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Atara Biotherapeutics Inc. Same sectorvia Eric Dobmeier
-
Avalyn Pharma Inc. Same sectorvia Erin Lavelle
-
Inhibikase Therapeutics Inc. Same sectorvia Mark T. Iwicki
-
Jasper Therapeutics Inc. Same sectorvia Lawrence Otto Klein
-
KALA BIO Inc. Same sectorvia Mark T. Iwicki
-
Neurogene Inc. Same sectorvia Erin Lavelle
-
Puma Biotechnology Inc Same sectorvia Allison Dorval
-
Relay Therapeutics Inc. Same sectorvia Habib J. Dable
-
Structure Therapeutics Inc. Same sectorvia Eric Dobmeier
-
Vera Therapeutics Inc. Same sectorvia Maha Katabi
-
Zura Bio Limited Same sectorvia Mark Eisner
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 2026 | Dahms Bradford D. Officer (Chief Financial Officer) | Grant or award | +37,813 | — | — |
| Feb 12, 2026 | Balta Elizabeth Officer (See Remarks) | Grant or award | +28,125 | — | — |
| Feb 12, 2026 | Tom Frohlich Director, Officer (Chief Executive Officer) | Grant or award | +78,750 | — | — |
| Feb 12, 2026 | King Andrew James Officer (See Remarks) | Grant or award | +41,250 | — | — |
| Oct 6, 2025 | Fairmount Healthcare Fund II L.P. Director, 10% owner | Grant or award | +1,333,126 | $9.14 | $12,184,772 |
| May 16, 2025 | Tom Frohlich Director, Officer (Chief Executive Officer) | Open-market purchase | +6,000 | $7.40 | $44,400 |
| Apr 28, 2025 | Peter Kolchinsky 10% owner | Other | +1,062,326 | — | — |
| Aug 1, 2024 | Dake Benjamin T Officer (SEE REMARKS) | Option exercise | +1,507 | $1.74 | $2,622 |
| Jul 31, 2024 | Dake Benjamin T Officer (SEE REMARKS) | Option exercise | +11,454 | $1.74 | $19,930 |
| Jun 17, 2024 | Rajeev M. Shah Director, 10% owner | Open-market purchase | +928,110 | $1.67 | $1,549,944 |
| Jun 14, 2024 | Eldridge George A Officer (SEE REMARKS) | Option exercise | +15,000 | $2.14 | $32,100 |
| Jun 14, 2024 | Verwijs Marinus Officer (CHIEF TECHNICAL OFFICER) | Option exercise | +10,600 | $14.59 | $154,654 |
| Jun 14, 2024 | Eldridge George A Officer (SEE REMARKS) | Open-market sale | −15,000 | $25.03 | $375,450 |
| Jun 14, 2024 | Verwijs Marinus Officer (CHIEF TECHNICAL OFFICER) | Open-market sale | −10,600 | $25.00 | $265,000 |
| Jun 13, 2024 | Gillies Hunter Officer (CHIEF MEDICAL OFFICER) | Option exercise | +6,000 | $2.14 | $12,840 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Jade Biosciences Inc.
Who is the CEO of Jade Biosciences Inc.?
Tom Frohlich has been Jade Biosciences Inc.'s Chief Executive Officer since April 2025.
How many directors are on Jade Biosciences Inc.'s board?
Jade Biosciences Inc.'s board has 18 directors: Allison Dorval, Christopher W. Cain, David S. Grayzel, Donald J. Santel, Eric Dobmeier, Erin Lavelle, Habib J. Dable, Joshua Resnick, Lawrence Otto Klein, Maha Katabi and 8 others.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="jade-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.